Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. Company
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:30 2022-06-24 am EDT
318.80 CHF   +4.08%
06/23Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis
AQ
06/23Novartis wins U.S. approval for targeted cancer drug combination
RE
06/21KENYA : Ministry signs agreement to enhance access to breast cancer treatment
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Number of employees : 100 920 people.
Sales per Business
20202021Delta
Pharmaceuticals46 491.0077%48 010.0072.9% +3.27%
Diagnostics13 852.0023%17 840.0027.1% +28.79%
CHF in Million
Sales per region
20202021Delta
United States28 630.0047.4%28 065.0042.6% -1.97%
Rest of Europe9 785.0016.2%11 381.0017.3% +16.31%
Rest of Asia8 627.0014.3%9 762.0014.8% +13.16%
Japan4 254.007%5 069.007.7% +19.16%
Germany3 352.005.6%4 319.006.6% +28.85%
Latin America2 393.004%2 746.004.2% +14.75%
Switzerland1 101.001.8%2 117.003.2% +92.28%
Africa, Australia and Oceania1 318.002.2%1 475.002.2% +11.91%
Rest of North America883.001.5%916.001.4% +3.74%
CHF in Million
Managers
Name Title Age Since
Severin Schwan Chief Executive Officer & Executive Director 54 2015
Alan Hippe Chief Financial & Information Officer 54 2011
Levi Garraway Chief Medical Officer - -
Pascale Schmidt Chief Compliance Officer 48 2020
Bruno Eschli, Dr. Head-Investor Relations - -
Annette Luther, Dr. Secretary 51 2020
Per-Olof Attinger Secretary-Executive Committee & Head-CEO Office 61 2010
Hans Clevers, Dr. Head-Pharma Research & Early Development 64 2022
Gallia G. Levy, Dr. Associate Group Medical Director-Hematology - -
Claudia Boeckstiegel General Counsel 57 2020
Members of the board
Name Title Age Since
Christoph Franz Chairman 62 2014
André S. Hoffmann Vice Chairman 64 2012
Bernard J. Poussot Independent Non-Executive Director 69 2015
Richard P. Lifton, Dr. Independent Non-Executive Director 68 2015
Claudia Süssmuth Dyckerhoff, Dr. Independent Non-Executive Director 54 2016
Julie Brown Independent Non-Executive Director 59 2016
Anita Hauser Independent Non-Executive Director 52 2017
Joerg Duschmale, Dr. Independent Non-Executive Director 37 2020
Patrick Frost Independent Non-Executive Director 53 2020
Severin Schwan Chief Executive Officer & Executive Director 54 2015
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 702,562,700 640,403,291 91.2% 62,159,409 8.8% 82.4%
Stock B 1 106,691,000 26,336,087 24.7% 0 0.0%
Shareholders
NameEquities%
Roche Holding AG 62,159,409 8.85%
The Vanguard Group, Inc. 19,530,678 2.78%
Norges Bank Investment Management 18,011,252 2.56%
BlackRock Fund Advisors 12,103,808 1.72%
Fidelity Management & Research Co. LLC 11,569,200 1.65%
UBS Asset Management Switzerland AG 9,004,985 1.28%
Credit Suisse Asset Management (Schweiz) AG 9,002,313 1.28%
Zürcher Kantonalbank (Investment Management) 6,808,174 0.97%
BlackRock Advisors (UK) Ltd. 5,893,467 0.84%
PRIMECAP Management Co. 5,560,379 0.79%
Holdings
NameEquities%Valuation
CHUGAI PHARMACEUTICAL CO., LTD (4519) 1,005,670,000 59.9% 27,579,805,838 USD
ROCHE HOLDING AG (ROG) 62,159,409 8.85% 21,166,168,266 USD
VAXCYTE, INC. (PCVX) 2,334,113 4.00% 55,995,371 USD
SENSEONICS HOLDINGS, INC. (SENS) 35,046,418 7.57% 40,653,845 USD
JASPER THERAPEUTICS, INC. (JSPR) 4,624,606 12.6% 14,660,001 USD
ALIGOS THERAPEUTICS, INC. (ALGS) 3,092,340 7.81% 3,989,119 USD
ELOXX PHARMACEUTICALS, INC. (ELOX) 4,998,936 5.77% 1,499,681 USD
TEMPEST THERAPEUTICS, INC. (TPST) 72,612 0.70% 209,123 USD
Company contact information
Roche Holding AG
Grenzacherstrasse 124
Basel, Basel-Stadt (Basle Town) 4058

Phone : +41.61.688.11.11
Fax : +41.61.691.93.91
Brand Portfolio
In partnership withAllbrands.markets
More brands of Roche Holding AG
Analysis
Credit Suisse looks secure, Sonova could bump SGS in Swiss SMI
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
ROCHE HOLDING AG-15.91%272 090
JOHNSON & JOHNSON5.02%479 678
ELI LILLY AND COMPANY13.21%293 110
PFIZER, INC.-15.17%289 466
ABBVIE INC.12.51%269 202
NOVO NORDISK A/S6.98%253 053
MERCK & CO., INC.21.52%235 508
ASTRAZENECA PLC24.31%205 217
NOVARTIS AG0.40%183 371
BRISTOL-MYERS SQUIBB COMPANY24.60%168 111
SANOFI13.52%132 461
AMGEN INC.9.07%131 077
GSK PLC9.17%109 224
BAYER AG22.96%59 888
DAIICHI SANKYO CO., LTD.13.23%46 990
CHUGAI PHARMACEUTICAL CO., LTD-4.42%43 454
TAKEDA PHARMACEUTICAL COMPANY LIMITED18.17%42 353
JIANGSU HENGRUI MEDICINE CO., LTD.-33.90%31 965
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-21.70%30 872
ASTELLAS PHARMA INC.16.44%29 455
CATALENT, INC.-14.39%19 644
Connections : Roche Holding AG